FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
Titel:
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
Auteur:
Cremolini, C. Loupakis, F. Masi, G. Lonardi, S. Granetto, C. Mancini, M.L. Chiara, S. Moretto, R. Rossini, D. Vitello, S. Allegrini, G. Tonini, G. Bergamo, F. Tomasello, G. Ronzoni, M. Buonadonna, A. Bustreo, S. Barbara, C. Boni, L. Falcone, A.